Victoria, British Columbia, Canada, September 21st, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is proud to announce that our CSO, Dr. Deanna Dryhurst, has been selected as part of The CDRD Academy’s Executive Institute inaugural cohort.
The 10 month, focused, executive development program has been custom designed with the Center for Creative Leadership to ensure that the Canadian life sciences sector has the executive talent to lead the industry into the future. Dr. Dryhurst, along with a limited number of high potential scientists and business professionals from across Canada, will participate in this unique program that combines researched and proven best practices/principles with targeted industry topics to take participants on a leadership journey.
The Centre for Drug Research and Development, with support of Pfizer Canada, announced the launch of the Executive Institute program, a distinct stream of The CDRD Academy, earlier this year. The CDRD Academy was created to deliver on a critical part of CDRD’s Mission: To uniquely train highly qualified personnel to drive the development of innovation.
Dr. Dryhurst joined ImmunoPrecise Antibodies in 2010, receiving an NSERC Industrial Research & Development Postdoctoral Fellowship to work on a rabbit monoclonal antibody development platform, where she was key in the development of ImmunoPrecise’s B cell technology. As Chief Scientific Officer, she leads R&D at ImmunoPrecise and is responsible for the prioritization of research projects, alignment with corporate strategy, and developing new product and service introductions.
About The Centre for Drug Research and Development (CDRD)
CDRD is Canada’s national life sciences venture, powering the country’s life sciences industry by creating and growing companies of scale – while training the scientific and business talent needed to drive them to become leading global anchors for Canada. We do this by building collaborations with the very best partners from academia, industry, patient foundations, the investment community, and other Key Opinion Leaders (KOLs), and providing the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients. www.cdrd.ca
About the CDRD Academy
The CDRD Academy was created to deliver on a critical part of the organization’s mission: To uniquely train the next generation of highly-qualified personnel to drive the development of innovation. The Academy currently encompasses three distinct streams: The Executive Institute, the Post-Graduate Institute and the Undergraduate Institute. Each provides a customized training program to the ensure that the Canadian life sciences sector has the scientific and management talent to lead the world. The Academy is firmly committed to addressing issues of gender disparity, and to supporting diversity in the Canadian life sciences sector. www.cdrd.ca/cdrd-academy/
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands.
The services offered to clients include antibody discovery in wild-type and transgenic mouse and rat models, custom phage display libraries, and rabbit monoclonal antibodies, all against a broad spectrum of antigens. The Company also offers B-cell screening and sorting services that may decrease discovery timelines and enhance the probability of finding a therapeutic antibody of interest. In addition, the Company provides a broad range of additional services related to its biotherapeutic discovery platforms including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, phage display, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. Cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO and President
3204-4464 Markham Street
Victoria, BC V8Z 7X8
For investor relations please contact:
Email: [email protected]
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.